Novartis pelacarsen misses Phase 3 primary endpoint versus placebo
Novartis said pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce the risk of cardiovascular events versus placebo, including deaths, heart attacks and strokes.
By Elias SchisgallNovartis said a heart disease drug did not meet its primary endpoint in a Phase 3 study.The company on Friday said that the drug, pelacarsen, did not reduce the risk of cardiovascular events--including deaths, heart attacks, and strokes--compared to a placebo.The drug did succeed…